MEDIA

NEWS ARCHIVES

Interface Biologics Announces $1 Million Investment By Ontario’s Investment Accelerator Fund – Life Sciences
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, announces a $1 million investment by the Investment Accelerator Fund-Life Sciences (IAF-LS).

Toronto, Canada, December 6, 2011 – For Immediate Release

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, announces a $1 million investment by the Investment Accelerator Fund-Life Sciences (IAF-LS).

The IAF-LS program helps accelerate the growth of life sciences companies in Ontario. The fund invests up to $1,000,000 in seed and later stage financing in companies that have the potential to be global leaders in their field and provide sustainable economic benefits to Ontario. Funded by the Government of Ontario, the fund is a $7 million program that helps innovative life sciences companies turn their discoveries into new products and services that meet patient needs.

IBI's unique materials improve the safety and effectiveness of medical devices without changing the mechanical or functional properties of the device and with minimal manufacturing changes. Specific applications include thrombus reduction in blood contacting medical devices without the need for heparin and a more effective drug coated balloon to reduce restenosis in peripheral applications. As part of the IAF-LS funding, IBI will be exploring the use of its technology platforms in ophthalmology applications.

Barry Gekiere, Managing Director, Investment Accelerator Fund, commented "We are pleased to support Interface Biologics through our Life Sciences fund. We have been impressed with both the technical and commercial progress they have made to date and look forward to supporting their continued efforts."

Tom Reeves, CEO of IBI, commented "We are very pleased that the IAF-LS has chosen IBI as one of the limited number of life sciences companies they are funding. This underscores IBI's historical success and future opportunities. In particular, we are excited about investigating the use of our technology platforms in ophthalmology applications – a large and growing market with significant unmet needs."

About Interface Biologics Inc.
Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. IBI’s primary technology focus areas are anti-thrombogenic devices that reduce thrombosis without the need for heparin, anti-infective polymers, and programmable combination drug delivery devices. IBI, a University of Toronto spinoff, is located at the MaRS Centre in Toronto, Canada. For more information about Interface Biologics, please visit www.interfacebiologics.com

About The Investment Accelerator Fund-Life Sciences Program
The Investment Accelerator Fund-Life Sciences (IAF-LS) helps accelerate the growth of life sciences companies in Ontario. The fund invests up to $1,000,000 in seed and later stage financing in companies that have the potential to be global leaders in their field and provide sustainable economic benefits to Ontario. Funded by the Government of Ontario, the fund is a $7-million program that helps innovative life sciences companies turn their discoveries into new products and services that meet patient needs. The IAF-LS is delivered by MaRS . For more information, please visitwww.marsdd.com/iaf-lifesciences

FOR FURTHER INFORMATION PLEASE CONTACT:
Julie Fotheringham - Partner, Hageman Communications
416-951-7988
Julie.fotheringham@hageman.ca

Powered by Innovasium